G-DEFINER

@GDefiner project investigated the #gender inequalities among #cancer patients in the development of immune-related adverse events associated with #immunotherapy treatment across 4 countries 🇮🇹🇸🇪🇳🇴🇮🇪 Presentation of study outcomes👉📺 t.ly/czQ4W

#dirittoallobliooncologico: una battaglia di civiltà che segna la fine di troppe discriminazioni subite finora dai cittadini che sono guariti dal cancro. Leggi di più qui: medinews.it/comunicati/dir… @favo_it @AiomFondazione #iononsonoilmiotumore

Dear Twitter, listen to 🇮🇪 🇮🇹🇳🇴🇸🇪@GDefiner coordinator Ros @AlbaMiceli and find out more on #Cancer therapy and sex & #gender inequalities in immune-related adverse events with immunotherapy treatment 👇 RT welcome 📣 youtu.be/qcxP_31tK1M

“Female researchers are more read and less cited because they more often engage in research for societal progress.” blogs.lse.ac.uk/impactofsocial…

@ProfJohnCrown @GDefiner identifying how gender plays a role in how people have adverse immune related events associated with their immunotherapy.

Is there a way we can make the immunotherapy results in metastatic uveal melanoma better? @Dr_Alex_Eustace and the @CCRTIreland team are also trying to explain gender differences in immunotherapy as part of the international @G-Definer study.

We are also collaborating with other international colleagues on the G-Definer study looking at gender differences in immunotherapy outcomes. @Dr_Alex_Eustace is leading our effort here.